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Increasing interest in the vascular features of sclero­
derma has led to the hypothesis that the blood vessel is 
the major target tissue and that the endothelial cell is 
the principal cell target. Useful observations stemming 
from the vascular hypothesis include the use of micro­
vascular abnormalities in the early detection of the pa­
tient destined to develop classical scleroderma, the dis­
covery of a serum protease selectively cytotoxic to en­
dothelial cells, and the study of a serum mitogenic activ­
ity for fibroblasts in scleroderma patients. Immune 
events related to the vascular lesions are under active 
study but have not as yet provided a unique immunolog­
ical lesion in scleroderma patients. The possibility that 
immunity to basement membrane (type IV) collagen may 
be selective for scleroderma patients deserves further 
study. Persistent immunity to endothelial basement 
membrane structures would provide a basis for contin­
ued endotbelial injury. Techniques to quantify endothe­
lial injury are useful to assess activity of the vascular 
lesions and to monitor therapies designed to block fur­
ther vascular injury. The definition of pre-fibrotic vas­
cular lesions may have future therapeutic and preven­
tive implications for scleroderma. 
Scleroderma is at once the easiest connective tissue disorder 
to recognize and the most difficult to understand [1, 2]. This 
essay will discuss recent observations in our understanding of 
the diffuse or generalized form of scleroderma. 
Scleroderma subjects demonstrate a remarkable propensity 
to deposit large quantities of collagenous matrix in unusual sites 
throughout the body, best appreciated at a glance or a touch in 
the skin. Analyses of this matrix suggest that it is similar to 
collagens deposited in other human fibrotic disorders, such as 
cirrhosis (liver), emphysema (lung), keloids (skin) and athero­
sclerosis (blood vessels), and consists of the usual 4:1 ratio of 
collagens types I and III [3]. The cell most likely responsible 
for this excess collagen is the interstitial fibroblast_ The stimulus 
for increased collagen deposition is unknown and could repre­
sent increased synthesis per fibroblast, increased amplification 
or migration of fibroblasts, or decreased collagen degradation. 
Initial in vitro studies of scleroderma skin fibroblasts, which 
were not rigorously controlled for fibroblast proliferation, dem­
onstrated increased collagen synthesis per cell [4,5]. Recent 
studies have confirmed this increased synthesis and have found 
levels of collagenase to be similar to levels in control cells, 
suggesting that increased synthesis of collagen is more impor­
tant in scleroderma than is decreased collagen degradation 
[3]_ The level of regulation accounting for this increased syn­
thesis is completely unknown. Most studies of potential regu­
latory compounds have shown few differences between healthy 
skin and scleroderma fibroblast responses [6]. As an example, 
the N-terminal propeptide of type I collagen inhibits overall 
collagen synthesis in both scleroderma and healthy skin fibro­
blasts [7]. Mitogens such as platelet derived growth factor, 
fibroblast growth factor, and nerve growth factor have an equal 
mitogenic effect on scleroderma and healthy fibroblasts [6]. 
The multifactorial mitogen serum stimulates both equally. Re­
cently several laboratories have reported in preliminary form 
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that scleroderma serum contains a mitogen selective for fibro­
blasts [8,9]. We have confirmed the presence of a mitogen in 
scleroderma serum selective for healthy human skin fibroblasts 
and extended these observations to show that this mitogen has 
little to no effect on scleroderma fibroblasts and that the 
mitogenic effect of scleroderma serum, but not that of healthy 
serum, can be blocked completely by inhibitors of proteolytic 
enzymes such as soybean trypsin inhibitor (Kunitz type*)_ With 
the identification of a mitogen in scleroderma serum, two mech­
anisms by which scleroderma fibroblasts could develop an 
enhanced capacity to synthesize collagen must be entertained. 
The simplest would be direct stimulation of the fibroblast to 
selectively increase collagen synthesis by an as yet unknown 
stimulus emanating from the early vascular and inflammatory 
stages of the disease. If present such a single and selective 
stimulus remains to be detected. The second mechanism would 
include increased fibroblast replication and consequently am­
plification of the collagen producing capacity of a given region 
such as the subcutaneous space by increasing the number of 
fibroblasts. If replication were an isolated event and each 
daughter fibroblast were equivalent to the parent cell in its 
capacity to synthesize collagen, this second mechanism would 
not explain the demonstrated increased capacity of scleroderma 
fibroblasts to synthesize collagen on a per cell basis. Further­
more, scleroderma fibroblasts studied in vitro have not shown 
abnormal growth characteristics [3-5,10]. They have shown a 
lack of response to the scleroderma serum mitogen which could 
be interpreted as evidence of in vivo exposure to this mitogen_ 
The existing data are consistent with both of these mechanisms 
being operative, i.e., both fibroblast replication and increased 
collagen synthesis are mechanisms of fibrosis in scleroderma. 
In this situation the fibroblast would be analogous to lympho­
cyte populations which simultaneously replicate and increase 
their phenotypic expression of mediator production, such as 
lymphokine synthesis. It is conceivable that fibroblasts respond 
to similar types of stimuli as do lymphocytes_ More detailed 
studies of the interactions between cells and modulators of the 
immune system and of the interstitial connective tissue are 
needed_ 
Replication is not the only mechanism by which fibroblast 
expression can be amplified. In vitro studies suggest that short 
sequences in the collagen molecule stimulate fibroblast che­
motaxis in Boyden chambers [11]. Whether fibroblast migration 
is an important mechanism in human fibrotic disease remains 
to be demonstrated. 
Developmental studies of fibroblast behavior suggest that 
enhanced levels of collagen synthesis are an inherent trait of 
the life history of interstitial cells in which fibroblasts mature 
into fibrocytes with at least three stages recognizable morpho­
logically and with only the final stage producing substantial 
quantities of collagen. Thus fibroblast replication alone could, 
by increasing the proportion of high collagen-producing mature 
fibrocytes in the interstitium of scleroderma skin, lead to both 
fibroblast amplification and increased synthesis of collagen on 
a per cell basis [12]. Careful cloning studies of scleroderma and 
control fibroblasts might demonstrate such an increased pro­
portion of high collagen producing fibrocytes [13]. 
Immune reactions to types I and IV collagens have been 
demonstrated in both serum and lymphocytes from scleroderma 
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subjects [11,14]. A perpetuating cycle of fibrosis could develop 
from fibroblast proliferation --> fibrocyte collagen synthesis --> 
a host response susceptibility to develop an immune response 
to collagen components --> activated lymphocytes-monocytes 
--> mediator release --> fibroblast proliferation. 
It has been known for several decades that the vascular 
abnormalities, particularly the proliferative lesion of the small 
arteries, are key to the ultimate prognosis in the individual 
patient through the mechanism of visceral insufficiency of the 
kidneys, lungs, heart, and gastrointestinal systems, any of which 
can lead to death [1,2,15]. Over the years several colleagues 
have attempted to study the mechanisms of vascular damage 
in scleroderma. Taking a clue from the careful ultrastructural 
studies of Fleischmajer and colleagues which demonstrated 
damage to the endothelial lining cell of the blood vessel [16], 
Kahaleh, Sherer, and LeRoy examined the effect of scleroderma 
serum on the growth of umbilical cord endothelial cells in l'itro. 
They found most scleroderma sera to contain an activity which 
was cytotoxic to endothelial cells [17]. This endothelial cyto­
toxic activity could be blocked by protease inhibitors suggesting 
that a protease or protease-inhibitor complex could be the 
active endothelial cytotoxic principle.t It is fascinating to realize 
that the same scleroderma sera contain activities which kill 
endothelial cells and stimulate fibroblasts and that both these 
activities are blocked by protease inhibitors. It is not known 
whether the same protease molecules effect both endothelial 
cytotoxicity and fibroblast proliferation. 
What could be the source of such a protease or proteases in 
scleroderma? The possibilities are myriad. There is a substan­
tial amount of evidence that abnormalities of the immune 
system are associated with scleroderma [2]. It has been shown 
that activated mononuclear cells can release lymphokines and 
that some (interleukin I) of these are protease in nature [18]. 
Mononuclear cell supernatants have been shown to stimulate 
fibroblasts and this stimulation is abrogated by protease inhib­
itors [19]. So a contender for the source of the scleroderma 
serum protease is activated monocytes perhaps under lympho­
cyte control directed against as yet unknown vascular or cuta­
neous antigens. 
Many other possible sources of protease exist. Surface acti­
vatable Hageman factor can initiate the activation of proteases 
via the coagulation cascade, the kinin pathway, and the acti­
vation of the complement system [20]. All cells contain pro­
teases and their presence may mirror no more than the residue 
of cell damage. Rapidly dividing cells of all types secrete pro­
teases into the medium, so that a serum protease could be the 
result rather than the cause of fibroblast or endothelial prolif­
eration [21]. Platelets also contain proteases and may release 
portions of their protease contents by the sequence of adhesion­
aggregation-and release of 0: granules. In scleroderma patients, 
platelets could be concentrated at sites of endothelial injury. It 
is known from the work of Kahaleh et al that a platelet 0: 
granule protein, ,B-thromboglobulin, is increased in the serum 
of scleroderma patients [22]. Thus platelets are active in scle­
roderma and they could represent a source of protease. 
Monocyte-macrophage cells are prime suspects for the source 
of proteases. Very large quantities of broad spectrum proteases 
are secreted by activated macrophages [23]. Enzymes such as 
macrophage elastase have a broad spectrum of substrate affin­
ities and could be putatively released in scleroderma lesions 
[24]. What would be the mechanism of activation of monocytes­
macro phages? Macrophage activation is a concomitant of most 
immune responses. There is evidence that lymphocytes from 
scleroderma subjects secrete macrophage migration inhibitory 
factor in response to partially characterized normal cutaneous 
antigens [25]. These antigens could also be of vascular origin, 
which would attract activated immune cells to the endothelial 
cell or to basement membrane and provide further mechanisms 
for endothelial and vascular injury. Direct evidence for immu-
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nity against endothelial cell antigens in scleroderma has not 
been reported. Indirect reports of antibodies removed from 
scleroderma lymphocytes which recognize endothelial cells 
have appeared [26]. Mackel, DeLustro and associates have 
observed humoral immunity to basement membrane antigens, 
specifically IgG antibodies to type IV collagens, in the serum of 
scleroderma subjects [14]. Drawing analogies from the rheu­
matoid arthritis-like disease which develops in experimental 
animals rendered immune to cartilage or type II collagen [27], 
it is a distinct possibility that the diffuse connective tissue 
diseases, specifically scleroderma, represent autoimmune dis­
ease to basement membrane antigens, specifically to type IV 
collagen. This is an exciting possibility which can be subjected 
to experimental confirmation and which holds the potential of 
developing an experimental model for scleroderma, a much 
needed model for pathogenetic and therapeutic studies. Exclu­
sive focus on type IV collagen as the only potential basement 
membrane antigen would be unwise; the attachment protein 
laminin and less well characterized basement membrane gly­
coproteins should also be tested as putative antigens in sclero­
derma. 
The endothelial, intimal arterial lesion is not the only vas­
cular abnormality in scleroderma; distinctive microvascular 
abnormalities of morphology and function exist in the nailfold 
capillary bed. Maricq et al have described a widefield capillary 
pattern characteristic of scleroderma and scleroderma-spec­
trum disorders which consists of dilated, distorted capillary 
loops interspersed with regions of absent or diminished capillary 
loops. There is preliminary reason to suspect that the dilated 
loops are permanent features of the scleroderma capillary pat­
tern and that the avascular areas suggest recent or "active" 
disease.:j: Truly prospective testing of this "active pattern" 
concept is needed. On the functional side of the microvascula­
ture, scleroderma subjects are extremely sensitive to capillary 
standstill, a complete cessation of capillary flow on gentle 
cooling. Capillary standstill should be a very useful procedure 
to test therapeutic agents with regard to preventing microvas­
cular insufficiency [28]. Such agents might have a role in the 
management of scleroderma. 
An orientation toward vascular aspects of scleroderma might 
substantially improve the presently dismal management situa­
tion. If one realizes that fibrotic manifestations are extremely 
difficult to quantify and that activity of fibrotic features is 
virtually impossible to assess, it is not difficult to set fibrotic 
features aside and focus on vascular features. Here quantifica­
ton can be immediate and of many types. The most straight­
forward to monitor are the global assays of endothelial and 
vascular damage which would include serum endothelial cyto­
toxic activity, serum factor VIII-von Willebrand factor levels 
(a protein complex produced only by the endothelial cell and 
elevated in states of endothelial perturbation; [29], serum (3-
thromboglobulin levels, and platelet aggregate ratios. It is pre­
mature to predict which one of these assays will provide the 
optimal single test for monitoring vascular injury in sclero­
derma. This hattery of assays to monitor endothelial damage 
can provide quantitative measures of the degree and the activity 
of vascular disease in scleroderma. Therapies in this disease can 
be assessed over the short term hy determining which agents 
can return to normal the abnormal levels of this battery of 
endothelial tests. Noncompliance and inadequate dosing can be 
easily detected. Once a particular therapy has been shown to 
normalize tests of endothelial integrity, full double-blinded 
multicenter studies of particular agents can be undertaken to 
determine effects on the fibrotic features of scleoderma. Such 
a graduated approach to the therapy of scleroderma would 
seem to offer a more efficient basis for determining efficacy in 
scleroderma than the present empirical approach. 
Using a combined endothelial and microvascular armamen-
:j: Maricq HR, Harper FE, LeRoy EC: A prospective study of Ray­
naud phenomenon and early connective tissue disease: Microvascular 
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tarium, it seems likely that one can detect a prescleroderma 
population of patients from the heterogeneous group of subjects 
who exhibit Raynaud's phenomenon. Therapeutic attempts to 
prevent the fibrotic features of scleroderma would seem to offer 
much more than present attempts to remove fibrosis once it 
has occurred. 
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